Findings

What do systematic reviews say?

22 questions · 22 findings · 2 reviews

No studies found 3 · 13.6%GRADE not reported 2 · 9.1%Very low 1 · 4.5%Low 10 · 45.5%Moderate 6 · 27.3%High 0 · 0%

Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 727 participants
Low

Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
RR 0.89 [0.81, 0.97]
2 studies · 1423 participants
Low